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Diabetic nephropathy (DN) is the primary cause of morbidity and mortality in patients with type 1 diabetes mellitus (T1DM) and affects
about 30% of these patients.We have previously localized a DN locus on chromosome 3q with suggestive linkage in Finnish individuals.
Linkage to this region has also been reported earlier by several other groups. To ﬁne map this locus, we conducted a multistage case-
control association study in T1DM patients, comprising 1822 cases with nephropathy and 1874 T1DM patients free of nephropathy,
from Finland, Iceland, and the British Isles. At the screening stage, we genotyped 3072 tag SNPs, spanning a 28 Mb region, in 234
patients and 215 controls from Finland. SNPs that met the signiﬁcance threshold of p < 0.01 at this stage were followed up by a series
of sample sets. A genetic variant, rs1866813, in the noncoding region at 3q22was associatedwith increased risk of DN (overall p¼ 7.073
106, combinedodds ratio [OR] of the allele¼1.33). The estimatedgenotypicORsof this variant in all Finnish samples suggested a codom-
inant effect, resulting in signiﬁcant association, with a p value of 4.73 105 (OR¼ 1.38; 95% conﬁdence interval¼ 1.18–1.62). Addition-
ally, an 11 kb segment ﬂanked by rs62408925 and rs1866813, two strongly correlated variants (r2¼ 0.95), contains three elements highly
conserved across multiple species. Independent replication will clarify the role of the associated variants at 3q22 in inﬂuencing the risk
of DN.Introduction
Diabetic nephropathy (DN) is the single most common
cause of end-stage renal disease (ESRD) in the Western
world, accounting for about 40% of new cases of ESRD in
the USA.1,2 ESRD is an important cause of death in type 1
diabetes mellitus (T1DM) nephropathy.1 Clinically, DN is
a syndrome characterized by persistent proteinuria. The
hallmarks of DN pathology include renal extracellular-
matrix accumulation and thickening of the glomerular
basement membrane (GBM) and the tubular basement
membrane. However, the molecular pathomechanisms of
DN are currently obscure.
Accumulating evidence supports the notion that devel-
opment of the devastating kidney complications in diabe-
tes has genetic components. It has clearly been docu-
mented that only a subset (~30%) of patients with type 1
diabetes are susceptible to DN.3,4 The incidence of DN
peaks during the second decade in patients with T1DM,
and it declines thereafter.3,4 Familial clustering of DN has
been reported by several investigators.5–7 These family-
based studies have suggested that segregation of DN does
not follow simple Mendelian rules and that, instead, the
disease alleles signiﬁcantly increase the risk of DN among
siblings. Extensive efforts have been made to identify loci
for DN with the use of either genome-wide scans or candi-
date-gene approaches, but so far no genes have been asso-Thciated with DN in replica studies.8 Our previous genome-
wide scan using Finnish discordant sib pairs suggested
linkage to chromosome 3q.9 The 3q locus linked to DN
was repeatedly reported by linkage studies using either ge-
nome scans or a candidate-region approach.10–12 In partic-
ular, linkage signals on the 3q region were also detected by
two previous large genome scans, which used concordant
affected sib pairs10,12 because discordant-sib-pair analysis
without parent genotypes is theoretically not robust to
potential genotyping errors. Those results, together with
data from others, suggest that the 3q region is likely to
harbor susceptibility gene(s) for DN. In the present study,
we ﬁne mapped this locus by genotyping highly dense
single-nucleotide polymorphisms (SNPs) in 1822 cases
and 1874 controls from three populations (Finland, Ice-
land, and the British Isles). Here, we report the association
of genetic variants at 3q22 with an increased risk of DN.
Subjects and Methods
Study Subjects
The cross-sectional study includes a total of 1822 patients with
T1DM and nephropathy and 1874 patients with T1DM but with-
out nephropathy (controls) from Finland, Iceland, and the British
Isles. Themain clinical characteristics of these individuals are sum-
marized in Table 1. All participants provided written, informed
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Table 1. Main Clinical Characteristics of 3696 Patients with Type 1 Diabetes Included in the Study
Panel 1 Panel 2 Panel 3 Panel 4 Panel 5
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Number 235 215 330 175 459 628 80 107 718 749
Male/female (%) 53/47 45/55 61/39 38/62 62/38 46/54 69/31 54/46 58/42 43/57
Age (yrs) 515
9.3
49.65
10.9
39.35
9.5
42.65
7.6
53.65
10.1
43.85
12.8
52.55
16.4
54.45
16.4
49.65
10.4
44.95
11.2
Diabetes
duration (yrs)
32.95
8.6
30.75
9.1
27.55
7.9
305
2.8
31.25
8.4
26.85
9.6
25.15
9.3
25.85
8.7
34.55
9.6
29.65
9.1
Blood pressure
Systolic (mm Hg) 1525
16.3
133.95
18.3
1445
20
1325
17
148.45
21
129.25
15.9
1355
12.9
130.95
14.6
145.05
21.1
125.05
14.6
Diastolic (mm Hg) 82.95
8.6
78.95
7.3
84 5
11
785
9
83.85
10.9
78.35
9.2
80.15
7.6
77.95
6.1
81.85
11.4
75.35
7.7
Antihypertensive
therapy (%)
90.6 21.9 93 16.6 92.1 13.2 81.3 57.9 97.1 0
Retinal laser
treatment (%)
89.4 25.5 83.1 16.9 80.2 14.5 50 17.8 49.3 2.4
Renal status
Normoalbuminuriaa 0 215 (100%) 0 175 (100%) 0 628 (100%) 0 107 (100%) 0 749 (100%)
Macroalbuminuirab 162 (69%) 0 255 (77%) 0 274 (60%) 0 70 (88%) 0 489 (68%) 0
ESRDc 73 (31%) 0 75 (23%) 0 185 (40%) 0 10 (12%) 0 229 (32%) 0
a Normoalbuminuria is defined as the albumin excretion rate (AER) < 30 mg/24 hr or the albumin/creatinine ratio (ACR) < 3 mg/mmol in at least three
consecutive urine samples.
b Macroalbuminuria is defined as AER R 300 mg/24 hr or ACRR 30 mg/mmol in two of three consecutive measurements on sterile urine.
c End-stage renal disease.All study subjects had had T1DM for at least 10 years, with the
age at onset% 30 years. The renal status was based on the albumin
excretion rate (AER) in a 24 hr urine collection or the albumin/
creatinine ratio (ACR) in a random, spot urine collection. The
presence of ESRD was deﬁned according to whether patients
were undergoing dialysis or had had a kidney transplant. In addi-
tion to persistent macroalbuminuria, the concomitance of
retinopathy is one of the criteria required for a clinical diagnosis
of nephropathy in T1DM.1,13 Retinopathy status was assessed on
the basis of fundoscopy or retinal photography and information
about laser treatment. EstablishedDNwas deﬁned by (1) persistent
macroalbuminuria (AERR 300 mg/24 hr or ACRR 30 mg/mmol)
in two of three consecutive measurements or the presence of
ESRD; (2) the presence of retinopathy; and (3) the absence of clin-
ical or laboratory evidence of nondiabetic renal or urinary-tract
disease. Control status was deﬁned by the normoalbuminuria
(AER < 30 mg/24 hr or ACR < 3 mg/mmol) despite duration of di-
abetes for at least 15 years. The diagnostic criteria for the presence
of nephropathy were established prior to SNP genotyping.
The Finnish samples came from two sources: (1) the screening
panel (panel 1) and (2) follow-up cohorts from the Finnish
Diabetic Nephropathy study, FinnDiane (panels 2 and 3). Sample
collections from these two sources were carried out separately and
independently of each other. Panel 1 samples, used for the screen-
ing stage, were ascertained and recruited by the Department of
Public Health, University of Helsinki, Finland, as described else-
where,9 and close relatives of samples, including siblings and par-
ent-offspring, were excluded from this panel. The FinnDiane study
is a comprehensive, multicenter, nationwide project with the aim
to characterize 25% of all adult patients with T1DM in Finland,
and this project has been described elsewhere.14 A small-sized Ice-
landic cohort (panel 4), recruited at Landspı´tali University Hospi-6 The American Journal of Human Genetics 84, 5–13, January 9, 200tal in Reykjavı´k, Iceland, and a British Isles cohort (panel 5), re-
cruited in the UK and Ireland as part of multicenter DN-research
projects, were included as additional follow-up samples. As a mul-
tistage association study, individuals of panel 2 were genotyped for
the top SNPs that met the signiﬁcance threshold of 0.01 at the
screening stage. The additional follow-up study was performed
on panels 3, 4, and 5 if SNPs that met the signiﬁcance threshold
of 0.05 in panel 2 involved the same risk allele in panels 1 and
2. Because panel 1 and the two FinnDiane cohorts were recruited
independently throughout Finland, we excluded any overlap of
the sample collections prior to genotyping the top SNPs in panel
2. This was done with the implementation of a unique personal
identiﬁcation (ID) code, containing information on date of birth
and sex, as well as control digits.
The Ethical Committees of the Finnish National Public Institute
and the Karolinska Institutet approved the protocol. Regarding the
FinnDiane study, the local ethical committee at each FinnDiane
center approved the protocol. The Icelandic Data Protection Com-
mission and the National Bioethics Committee in Iceland have
approved the study. Ethical approval for recruitment of the British
Isles cohort was obtained from the appropriate Research Ethics
Committees in the UK and Ireland, and written, informed consent
was obtained from individuals prior to the study’s inception.
SNP Selection and Genotyping
At the screening stage, we took the region at 3q ranging from 124
to 152 Mb (NCBI build 35), corresponding to the region between
D3S1267 and D3S1308. This region covered our linkage peak and
also extended the coverage to include the linkage peak reported by
another study.11 We used the linkage disequilibrium (LD)-based
approach to select SNPs.15 In brief, SNP genotype data typed in9
the Centre d’Etude du Polymorphisme Humain (CEPH) collection
(CEU; 30 trios of northern and western European ancestry living
in Utah) in the region between 124 and 152 Mb was downloaded
from the HapMap database (see Web Resources). The Tagger pro-
gram, implemented in Haploview (see Web Resources), was ap-
plied for selection of tag SNPs with three-marker haplotype tests
(LOD R 2.0), so that all SNPs with a minor-allele frequency
(MAF) > 2% were captured with r2 R 0.7. We ﬁnally determined
a set of 3072 SNPs that passed Illumina quality design scores for
genotyping. The SNP density in the region was, on average, 1.1
SNPs per 10 kb, although the density is highly dependent upon
LD extent in this region.
At the screening stage, the selected tag SNPs were genotyped
in panel 1 with the Illumina BeadArrays, 96-array matrix, at the
Wallenberg Consortium North (WCN) SNP platform (Uppsala,
Sweden). At least 0.5 mg of genomic DNA, quantiﬁed with the
PicoGreen assay, was used for genotyping of each sample. The
genotype quality was evaluated with the PLINK program16 (see
Web Resources).We excluded SNPs if they showed (1) a genotyping
success rate < 90% in panel 1 cases and controls (2) an MAF < 2%
in panel 1 cases and controls, and (3) signiﬁcant deviation from
Hardy-Weinberg equilibrium (HWE) in the controls (p < 0.001).
Any samples that yielded < 85% of genotype rates were excluded.
For the follow-up study, we used the standard TaqMan allelic-
discrimination method (Applied Biosystems) to genotype all of
the putative loci that reached the signiﬁcance thresholds. The Taq-
Man SNP-genotyping assays were obtained from Applied Biosys-
tems. Some SNPs were genotyped via the sequencing method
with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems) if the TaqMan genotyping assays were not available.
We also checked whether genotypes of the follow-up SNPs showed
signiﬁcant deviation from HWE in controls.
Statistical Analysis
Statistical analyses were performed with the PLINK program (see
Web Resources). We assessed allelic association of the single
markers between cases and controls using standard c2 tests. ORs
for each individual allele and the corresponding 95% conﬁdence
intervals [CI] were calculated. All p values presented were two-
tailed. We used Fisher’s exact test to assess deviation of the geno-
type frequency from that expected under HWE in the controls.
To avoid any bias leading to signiﬁcant association, we checked
whethermissing rates between cases and controls for each SNP dif-
fered signiﬁcantly. The raw data combined from different popula-
tions was analyzed jointly with a Cochran-Mantel-Haenszelmodel
under the assumption of common relative risks. The Pearson c2
statistic was used to test for evidence of heterogeneity of the ORs
across studies. For detection of potential population stratiﬁcation
that might lead to spurious association, two methods, imple-
mented in the PLINK program, were performed, with the use of
all valid tag SNPs in panel 1: (1) the genomic-control method,17
which estimates the genomic inﬂation factor, l, on the basis of
the median distribution of the c2 statistics; and 2) the struc-
tured-association method,18 which clusters individuals into ho-
mogenous subsets with the distance-based clustering approach.
We performed clustering of individuals, by which each cluster
consists of at least one case and one control, with a threshold of
0.01 for the pairwise population concordance (PPC) test. l ¼ 1 in-
dicates a null distribution with no inﬂation of test statistics.
Logistic-regression analysis was performed to estimate geno-
typic OR and corresponding 95%CI for individual SNP genotypes,Thwith the Statistical Analysis System (SAS) program, version 9.1.3.
We estimated the regression coefﬁcients (b), logarithms of the
ORs for the genotypic effect, with the use of dummy variables
(c1, c2) to code the genotypes.
Pairwise LD was calculated by the Haploview program (see Web
Resources), with the use of the standard measures D0 and r2. We
used the expectation-maximization algorithm, implemented in
the Haploview program, to estimate haplotype frequencies. We
performed the c2 test for association of haplotypes, as well as
10,000 permutations, to obtain empirical p values in order to cor-
rect for multiple-testing bias.
Power calculations were performed with the use of a 1% signif-
icance level for detecting an association, assuming an additive
model with relative risk of 1.5 and disease-allele frequency of
20%. The calculations were performed with the online Genetic
Calculator software (see Web Resources).
We utilized the UCSC multiple-species genome alignment of 28
vertebrate species (20 mammals, including human, and 8 non-
mammalian vertebrates) of the UCSC genome browser (see Web
Resources) to localize evolutionarily conserved elements.
Results
Before the high-density SNP genotyping, we estimated the
power in panel 1 assuming an additive model with relative
risk of 1.5, yielding 75% power to ﬁnd association with
a p value of 0.01 (unadjusted), which was determined as
the signiﬁcance threshold for the follow-up study. At the
screening stage, we genotyped 3072 tag SNPs, spanning
the 28 Mb region from 124 to 152 Mb (NCBI build 35),
in panel 1. After performing the genotype quality control
(see Subjects and Methods), we included 2805 SNPs
(91.3%) and 444 samples (98.7%) in subsequent analyses,
resulting in initial associations (p < 0.01) of 27 SNPs
with DN in the allele-based test (Table 2). Two boundary
SNPs (rs13094003 and rs8052) of the targeted region
were still included among valid SNPs, suggesting that the
coverage of the successfully genotyped SNPs had no signif-
icant loss. We assessed population stratiﬁcation of panel
1 (444 samples) on the basis of 2805 SNPs using two ap-
proaches. With the use of the genomic-control method,
the inﬂation factor, l, was 1.06. With the structured-asso-
ciation approach, l was 1.06, based on the median distri-
bution of test statistics after individual clustering in which
each cluster had at least one case and one control. These re-
sults from two different methods indicated little evidence
for inﬂation in association-test statistics as a result of
population stratiﬁcation in panel 1.
To eliminate false-positive associations occurring by
chance, we then evaluated the 27 SNPs that met the signif-
icance threshold of 0.01 using panel 2. A single SNP,
rs1866813 (p ¼ 0.0049 at the screening stage), among
the 26 genotyped SNPs in panel 2 (one TaqMan SNP assay
for rs6440067 was unavailable) met the threshold for
moving on to panels 3–5 for further genotyping. The
minor allele C of rs1866813 in panel 2 was associated
with increased risk of DN (p ¼ 0.0088; OR ¼ 1.60; 95%
CI ¼ 1.12–2.28) (Table 2). At the second follow-up stage,e American Journal of Human Genetics 84, 5–13, January 9, 2009 7
Table 2. Summary of the Screening Stage in Panel 1 and the Follow-Up Study in Panel 2
Screening Stage in Panel 1 Follow-Up Study in Panel 2
SNP ID Position (bp) Minor Allele MAF Case MAF Control p Value MAF Case MAF Control p Value
rs1049296 134977044 T 0.069 0.146 1.83104 0.111 0.107 0.68
rs4678015 124583153 G 0.524 0.403 3.33104 0.473 0.459 0.36
rs12492285 144436293 A 0.168 0.094 0.0012 0.092 0.084 0.69
rs4395444 126210437 A 0.353 0.46 0.0012 0.414 0.418 0.91
rs12492170 138359517 A 0.299 0.21 0.0025 0.271 0.233 0.23
rs6801610 144331065 G 0.442 0.54 0.0034 0.524 0.53 0.86
rs1871349 144018107 G 0.154 0.231 0.0041 0.194 0.22 0.34
rs2712421 129770441 G 0.27 0.358 0.0042 0.332 0.302 0.37
rs6439127 129651111 A 0.052 0.102 0.0048 0.074 0.066 0.65
rs2587025 147731609 C 0.308 0.399 0.0048 0.359 0.345 0.68
rs1866813 138284628 C 0.218 0.144 0.0049 0.212 0.144 0.0088
rs3796180 138314818 T 0.296 0.215 0.0053 0.273 0.232 0.2
rs4679257 126239279 T 0.106 0.17 0.0053 0.107 0.146 0.082
rs6789065 144623118 A 0.274 0.36 0.0056 0.339 0.345 0.85
rs6805170 150328788 G 0.114 0.061 0.0057 0.146 0.112 0.15
rs4974501 135592551 A 0.42 0.33 0.0059 0.358 0.373 0.64
rs7648426 151504183 A 0.131 0.075 0.0065 0.092 0.094 0.94
rs1382270 138461351 C 0.418 0.33 0.0069 0.409 0.395 0.66
rs7628692 144564710 G 0.522 0.431 0.0071 0.455 0.436 0.58
rs7611217 144327151 G 0.394 0.308 0.0076 0.339 0.317 0.51
rs6803636 147599739 C 0.209 0.141 0.0084 0.17 0.201 0.27
rs33264 124892478 G 0.366 0.283 0.0086 0.361 0.364 0.93
rs4974491 135538571 C 0.312 0.396 0.0091 0.36 0.366 0.85
rs6440067 143407729 T 0.345 0.264 0.0092 ND
rs349558 141744377 T 0.086 0.141 0.0092 0.097 0.095 0.94
rs2659690 129664467 A 0.22 0.296 0.0093 0.278 0.251 0.37
rs7632370 146980190 T 0.487 0.401 0.0099 0.392 0.468 0.024
The 27 SNPs that met the significance threshold (p < 0.01) at the screening stage were genotyped in the follow-up study, and they are listed in order of
significance. Initial significances are highlighted in boldface if they reached the significance threshold (p< 0.05) in panel 2. Abbreviations are as follows:
MAF, minor allele frequency; ND, not done. Follow up was not done for rs6440067, because the SNP assay is not available from Applied Biosystems.we were also able to replicate the association for rs1866813
(Table 3) in panel 3 (p ¼ 0.03) and panel 4 (p ¼ 0.021). The
combination of all Finnish samples (panels 1–3) resulted in
signiﬁcant association (p ¼ 2.41 3 105; OR ¼ 1.42). Asso-
ciation of this SNP in panel 5 (the British Isles cohort) was
not signiﬁcant (p ¼ 0.235). To interpret the results as
a whole, we analyzed data from all cohorts (panels 1–5), us-
ing the Cochran-Mantel-Haenszel model, which yielded8 The American Journal of Human Genetics 84, 5–13, January 9, 200an overall two-tailed p value of 7.07 3 106 (OR ¼ 1.33;
95% CI ¼ 1.17–1.51) (Table 3). There was no evidence for
heterogeneity of ORs across studies (p > 0.05 for all) with
the Pearson c2 statistic used. The allelic association of
rs1866813withDNat 3q22 remained signiﬁcant, evenafter
a Bonferroni adjustment for 2805 SNPs tested (padjusted ¼
0.0198). The consistent ﬁnding of association in four out
of ﬁve cohorts provided evidence against the possibilityTable 3. Association Results for rs1866813 in All DN Cohorts
Population
Cases Controls
p Value Odds Ratio (95% CI)MAFa AA/AC/CCb MAFa AA/AC/CCb
Panel 1 Finland 0.218 143/77/12 0.144 155/51/5 0.0049 1.65 (1.16–2.34)
Panel 2 Finland 0.212 208/98/20 0.144 128/42/4 0.0088 1.60 (1.12–2.28)
Panel 3 Finland 0.202 296/131/26 0.165 427/161/20 0.03 1.28 (1.02–1.60)
Finnish combinedc 0.209 647/306/58 0.157 710/254/29 2.41 3 105 1.42 (1.20–1.66)
Panel 4 Iceland 0.194 52/25/3 0.109 85/19/2 0.021 1.98 (1.10–3.54)
Panel 5 British Isles 0.143 516/180/11 0.127 561/155/16 0.235 1.14 (0.92–1.41)
All combinedd 0.182 1215/511/72 0.142 1356/428/47 7.07 3 106 1.33 (1.17–1.51)
Minor-allele frequency and genotype counts in the cases and controls; the allelic ORs with 95% confidence intervals (95% CI) and the two-tailed p values on
an allele-based test are presented.
a Minor-allele frequency.
b Genotype counts.
c Samples include only Finnish samples (panels 1–3).
d Association for the C allele of rs1866813 was calculated in all samples (panels 1–5) with the Cochran-Mantel-Haenszel model.9
that our ﬁnding was due to population stratiﬁcation,
because it is unlikely that the same kind of stratiﬁcation
exists in each of these disparate population samples. How-
ever, the association of rs1866813 did not reach the
genome-wide signiﬁcance level, and further replication is
necessary for conﬁrmation of our ﬁndings.
We used logistic-regression analysis to estimate the
genotypic effects of rs1866813 on DN on the basis of all
Finnish samples (panels 1–3). The heterozygous carriers
have signiﬁcantly higher risk than do noncarriers (OR ¼
1.32; 95% CI ¼ 1.08–1.61; p ¼ 0.0056), whereas individ-
uals who are homozygous with respect to the C allele
have increased risk in comparison to heterozygous carriers
(OR ¼ 1.66; 95% CI ¼ 1.03–2.67; p ¼ 0.037). This impli-
cates a codominant allele-dose effect. We then tested for
association using a codominant model (additive genotype
coding), which resulted in a p value of 4.7 3 105 (OR ¼
1.38; 95% CI ¼ 1.18–1.62). The effect size of 1.38 was
not strong enough to account for the LOD score of 2.67
observed in our linkage study.9
In the haplotype analysis, we focused on the segment in
which rs1866813 is located. Tag SNPs ﬂanking 100 kb of
rs1866813 were selected. In total, 24 SNPs genotyped in
panel 1, spanning about 250 kb, were included for analysis
using the expectation-maximization algorithm (the Hap-
loview program). This analysis estimated ﬁve haplotype
blocks. A 44 kb block containing rs1866813 (138250708–
138294816 bp, NCBI build 36), ﬂanked by recombination
hotspots with multiallelic LDmeasures (D0) of 0.73 was ob-
served. This block consisted of four tag SNPs (rs17374749,
rs6766709, rs1866813, and rs16844489). Only ﬁve haplo-
types with a frequency > 5% in cases and controls in this
block were estimated, and they made up 99% of the total
chromosomes observed. The rs1866813 C-allele-carrying
haplotype (GTCT) was more frequently observed in the
cases than in the controls (21% in cases versus 14% in
controls, p ¼ 0.01) (Table 4). However, no haplotypes ob-
served showed stronger association than the single SNP
rs1866813 (p ¼ 0.0049) genotyped in panel 1.
The variant identiﬁed is located in a noncoding region
(~750 kb) between IL20RB [MIM 605621] and SOX14
[MIM 604747] and resides about 70 kb downstream of
a cluster of three genes; IL-20RB, NCK1 [MIM 600508],
and TMEM22 (Figure 1A). IL-20RB encodes the interleu-
kin-20 receptor B that is generally expressed in endothelial
cells,19 but its expression in human glomeruli was unde-
tectable by immunoﬂuorescence staining with two poly-
clonal IL-20RB antibodies (K-13 and K-17; Santa Cruz
Biotechnology) (data not shown). Nck1 is an intracellular
adaptor protein that is involved in actin polymerization.
In podocytes, Nck1 links the slit-diaphragm protein neph-
rin to the actin cytoskeleton, and this interaction has been
shown to be essential for nephrin-dependent reorganiza-
tion of actin in podocyte injury.20,21 Nck1 is also expressed
in endothelial cells, but its expression or role in DN has not
been reported. TMEM22 encodes a transmembrane protein
of unknown functions, but by RT-PCR, we were able toThdetect a low level of Nck1 expression in mammalian
glomeruli (data not shown).
It is unclear how the associated variant could inﬂuence
the development of DN, given that it resides about 70 kb
from the nearest genes, but it is possible that long-range
regulatory sequences are a part of the mechanism. To ex-
plore this, we analyzed the 44 kb block for the presence
of evolutionarily conserved genomic elements. Three
elements, designated HCS1, HCS2, and HCS3, which are
highly conserved (conservation scores > 75%) among
both mammals and nonmammalian vertebrates, were
identiﬁed in close vicinity of rs1866813 (Figure 1B).
We then sequenced the three conserved elements in
46 samples. Interestingly, a SNP, rs62408925, 500 bp
upstream of HCS1, showed a very high correlation with
the associated SNP, rs1866813 (r2 ¼ 0.95 and D0 ¼ 1.0).
After we genotyped this SNP (rs62408925) in panel 1 by se-
quencing, the T allele of rs62408925 was also signiﬁcantly
associated with increased risk of DN (p ¼ 0.0051). Thus,
the second associated variant in strong LD with
rs1866813 was identiﬁed. Because of its high correlation
with rs1866813, SNP rs62408925 can be estimated as
giving almost the same associations as rs1866813 in our
remaining panels. The three conserved sequences (HCS1,
HCS2, and HCS3) reside in the high-LD region (11 kb in
size) between rs62408925 and rs1866813. In addition,
a SNP, rs9826507, was detected within HCS1 and showed
no allelic association (p ¼ 0.10). However, individuals
homozygous for the A allele of rs9826507 had signiﬁcantly
reduced risk of DN, assuming the recessive model (p ¼
0.006; OR ¼ 0.38; 95% CI ¼ 0.19–0.77). Pairwise LD mea-
sures (D0 and r2) of these three SNPs were illustrated
(Figure 1C). We also performed haplotype analysis of three
Table 4. Estimated Haplotypes of Four SNPs, Consisting of
rs17374749, rs6766709, rs1866813, and rs16844489; and
Three SNPs, Consisting of rs62408925, rs9826507, and
rs1866813, in the rs1866813-Carrying Block in Panel 1
Haplotype Cases Controls c2 p Value pperm Value
b
Four SNP
Haplotypes (n ¼ 468a) (n ¼ 426)
GTAT 185 (0.395) 203 (0.477) 6.062 0.0138 0.1795
GAAT 92 (0.196) 71 (0.166) 1.338 0.2474 0.9997
GTCT 98 (0.21) 61 (0.144) 6.377 0.0116 0.1526
ATAT 58 (0.125) 65 (0.152) 1.343 0.2465 0.9997
GAAC 28 (0.06) 22 (0.052) 0.283 0.5947 1.0
Three SNP
Haplotypes (n ¼ 450) (n ¼ 420)
CGA 220 (0.49) 216 (0.513) 0.495 0.4819 0.8214
CAA 127 (0.281) 139 (0.332) 2.59 0.1076 0.2716
TGC 100 (0.222) 61 (0.145) 8.537 0.0035 0.0062
Estimated haplotype counts in cases and controls are presented, and corre-
sponding frequencies are shown in parentheses.
a Total chromosomal number in the group.
b The empirical p values were obtained on the basis of 10,000 permuta-
tions.e American Journal of Human Genetics 84, 5–13, January 9, 2009 9
Figure 1. Schematic View of the rs1866813-Carrying Region and Comparative Genomic Analysis
(A) Genomic structure in a 1.2 Mb interval (137.8–139 Mb, NCBI build 36) on chromosome 3q22. Black bars indicate five genes, and a gray
bar indicates the 44 kb haplotype block carrying rs1866813. Orientation of the genes is indicated with arrows.
(B) Multiple alignments of 28 vertebrate species, created with the 44 kb LD block in the UCSC Genome Browser (chr3: 138,250,700–
138,294,820 bp). Conservation scores for the placental mammal subset (17 species plus human) and a subset of ten other vertebrates10 The American Journal of Human Genetics 84, 5–13, January 9, 2009
SNPs (rs62408925, rs9826507, and rs1866813) on panel 1,
resulting in three common haplotypes (accounting for
99% of total haplotypes observed). The at-risk TGC haplo-
type was signiﬁcantly associated with DN (p ¼ 0.0035,
pperm ¼ 0.0062), showing a frequency of 22% in cases
and of 14.5% in controls. The frequency distribution of
the at-risk TGC haplotype between cases and controls
was very similar to that of the at-risk GTCT haplotype
(Table 4).
Discussion
In the present study, we have identiﬁed genetic variants, in
the noncoding region at 3q22, that are associated with
type 1 diabetic nephropathy in three Finnish cohorts.
The association was conﬁrmed in an Icelandic set. Further-
more, we found that a region very high in LD between two
correlated variants, associated with DN, contains three ele-
ments conserved across multiple species. It suggests that
the variants identiﬁed, together with susceptibility loci at
other chromosomal regions, might inﬂuence the risk of
DN through potential regulatory mechanisms. Our results
identifying associated variants in a noncoding region illus-
trate the advantage of unbiased ﬁne-mapping approaches
using high-density SNP genotyping, because a candidate-
gene approach at 3q might overlook this locus.22
Special emphasis was made to ensure authenticity of the
phenotypes of cases and controls. Thus, only cases with
macroalbuminuria or ESRD were accepted, whereas micro-
albuminria cases were excluded from the study. Also, al-
though a minimum of 15 years of normoalbuminuria after
the onset of diabetes is commonly used as criterion for con-
trols, some DN patients with a long duration of diabetes
might be incorrectly deﬁned as controls,23 especially as
a result of treatment with an ACE inhibitor or an angioten-
sin-receptor blocker.24 Therefore, efforts were made to en-
sure that none of control individuals had had proteinuria
at any stage despite their long duration of diabetes. The
MAF of rs1866813 in cases and controls matched perfectly
between panel 1 and panel 2. In panel 3, the MAF (16.5%)
of rs1866813 in controls was increased, compared to that
(14.4%) in panels 1 and 2, but the MAF in cases was com-
parable between the three Finnish panels. Here, control in-
dividuals in panels 1 and 2were thoroughly and repeatedly
followed up and characterized for at least 20 years. There-
fore, the phenotypes of these panels have higher conﬁ-
dence. However, panel 3 fulﬁlled only a single prospective
review, with relatively short follow-up after diagnosis ofThediabetes (15 years). Mild misclassiﬁcation in panel 3 might
lead to inconsistent MAF in controls, compared to that of
panels 1 and 2. This could explain why the associated
SNP (rs1866813) shows a very similar result between
panels 1 and 2, whereas only weak signiﬁcant association
was observed in panel 3. Another possibility for this result
is random ﬂuctuation in allele frequencies of the SNP in
panel 3, given that there was no evidence for heterogeneity
of ORs across the three Finnish panels. In addition, the
‘‘jackpot’’ effect25 could be a possible explanation for the
failure to ﬁnd association in the British Isles cohort; the re-
sult of sampling variations. The effect size might somehow
be overestimated in early samples, such as panels 1 and 2,
so that the true effect might not be easily detected in sub-
sequent studies. Thus, further replication across popula-
tions might clarify our ﬁndings.
The DN-associated variants are intriguing, although it is
positioned quite distant from genes within an apparent
noncoding region. A similar result has been reported for
a 9q locus in a genome-wide association study in patients
with type 2 diabetes.26 Here, the variants identiﬁed are lo-
cated about 70 kb downstream from a three-gene cluster
(IL-20RB, NCK1, and TMEM22). Two highly correlated var-
iants (r2 ¼ 0.95) associated with DN make up a strong LD
region that covers three conserved elements. It remains
to be shown whether or not genotypes of the associated
variants are correlated with gene-expression levels of the
nearby genes or whether these conserved elements are re-
ally cis-acting sequences that regulate expression of the
nearby genes.
The current understanding is that risk alleles for DN exist
in the general population but carriers do not develop DN
until long-term exposure to hyperglycemia has occurred.
Given that the ﬁrst manifestation of DN ismicroalbuminu-
ria, glomerular endothelial cells and podocytes might be
affected ﬁrst. Therefore, expression of target gene(s) inﬂu-
enced by the risk variants should be detectable in these
cells. The IL-20RB gene may be excluded, because its
expression in glomeruli was not observed. Both NCK1
and TMEM22 genes were expressed in glomeruli. Nck1
has been shown to be a crucial link between phosphory-
lated nephrin and the actin cytoskeleton during the devel-
opment of podocyte foot processes, as well as in their re-
generation during repair of effaced foot processes after
glomerular injury.20,21
At the present, we cannot explain how the variants iden-
tiﬁed can contribute to abnormal renal extracellular-
matrix accumulation and consequent GBM thickening in
hyperglycemia. However, the present results indicate that(eight nonmammalian species, platypus, and opossum) are displayed as a histogram in the upper panel, in which the height reflects the
size of the score. Short vertical lines indicate positions of four SNPs. Pairwise alignments of each species with the human genome are
displayed below the histogram, where the species aligned are listed on the left side. A grayscale density plot indicates alignment quality.
Vertical blue bar and green square brackets suggest discontinuities in the genomic context of the aligned DNA in the aligning species.
(C) Schematic view of three conserved elements (HCS1, HCS2, and HCS3) in an 11 kb region between rs62408925 and rs1866813 and
pairwise LD measures of rs62408925, rs9826507, and rs1866813 were illustrated in the lower panel. Black bars indicate conserved
elements. Red blocks indicate D0 ¼ 1.0, and the white number in the blocks indicates the value of r2.American Journal of Human Genetics 84, 5–13, January 9, 2009 11
the associated variants might inﬂuence DN risk through
potential remote gene-control27 mechanisms.
Supplemental Data
Supplemental Data include a list of Finnish Diabetic Nephropathy
Study Groupmembers and can be found with this article online at
http://www.ajhg.org/.
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